Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache

Simon Akerman, Bruce Simon, Marcela Romero-Reyes

Research output: Contribution to journalArticle

Abstract

Vagus nerve stimulation (VNS) has been reported to be effective in the abortive treatment of both migraine and cluster headache. Using validated animal models of acute dural-intracranial (migraine-like) and trigeminal-autonomic (cluster-like) head pain we tested whether VNS suppresses ongoing and nociceptive-evoked firing of trigeminocervical neurons to explain its abortive effects in migraine and cluster headache. Unilateral VNS was applied invasively via hook electrodes placed on the vagus nerve. A single dose of ipsilateral or contralateral VNS, to trigeminal recording and dural-stimulating side, suppressed ongoing spontaneous and noxious dural-evoked trigeminocervical neuronal firing. This effect was dose-dependent, with two doses of ipsilateral VNS prolonging suppression of ongoing spontaneous firing (maximally by ~ 60%) for up to three hours, and dural-evoked (Aδ-fiber; by ~ 22%, C-fiber: by ~ 55%) responses for at least two hours. Statistically, there was no difference between ipsilateral and contralateral groups. Two doses of VNS also suppressed superior salivatory nucleus-evoked trigeminocervical neuronal responses (maximally by ~ 22%) for 2.5 h, to model nociceptive activation of the trigeminal-autonomic pathway. VNS had no effect on normal somatosensory cutaneous facial responses throughout. These studies provide a mechanistic rationale for the observed benefits of VNS in the abortive treatment of migraine and cluster headache. In addition, they further validate these preclinical models as suitable approaches to optimize therapeutic efficacy, and provide an opportunity to hypothesize and dissect the neurobiological mechanisms of VNS in the treatment of primary headaches.

Original languageEnglish (US)
Pages (from-to)96-104
Number of pages9
JournalNeurobiology of Disease
Volume102
DOIs
StatePublished - Jun 1 2017

Fingerprint

Vagus Nerve Stimulation
Headache
Neurons
Migraine Disorders
Cluster Headache
Autonomic Pathways
Unmyelinated Nerve Fibers
Vagus Nerve
Electrodes
Skin

Keywords

  • Cluster headache
  • Migraine
  • Trigeminal autonomic
  • Trigeminovascular
  • Vagus nerve stimulation

ASJC Scopus subject areas

  • Neurology

Cite this

Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache. / Akerman, Simon; Simon, Bruce; Romero-Reyes, Marcela.

In: Neurobiology of Disease, Vol. 102, 01.06.2017, p. 96-104.

Research output: Contribution to journalArticle

Akerman, Simon; Simon, Bruce; Romero-Reyes, Marcela / Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache.

In: Neurobiology of Disease, Vol. 102, 01.06.2017, p. 96-104.

Research output: Contribution to journalArticle

@article{215109de496244c2bfb23742b7f75171,
title = "Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache",
abstract = "Vagus nerve stimulation (VNS) has been reported to be effective in the abortive treatment of both migraine and cluster headache. Using validated animal models of acute dural-intracranial (migraine-like) and trigeminal-autonomic (cluster-like) head pain we tested whether VNS suppresses ongoing and nociceptive-evoked firing of trigeminocervical neurons to explain its abortive effects in migraine and cluster headache. Unilateral VNS was applied invasively via hook electrodes placed on the vagus nerve. A single dose of ipsilateral or contralateral VNS, to trigeminal recording and dural-stimulating side, suppressed ongoing spontaneous and noxious dural-evoked trigeminocervical neuronal firing. This effect was dose-dependent, with two doses of ipsilateral VNS prolonging suppression of ongoing spontaneous firing (maximally by ~ 60%) for up to three hours, and dural-evoked (Aδ-fiber; by ~ 22%, C-fiber: by ~ 55%) responses for at least two hours. Statistically, there was no difference between ipsilateral and contralateral groups. Two doses of VNS also suppressed superior salivatory nucleus-evoked trigeminocervical neuronal responses (maximally by ~ 22%) for 2.5 h, to model nociceptive activation of the trigeminal-autonomic pathway. VNS had no effect on normal somatosensory cutaneous facial responses throughout. These studies provide a mechanistic rationale for the observed benefits of VNS in the abortive treatment of migraine and cluster headache. In addition, they further validate these preclinical models as suitable approaches to optimize therapeutic efficacy, and provide an opportunity to hypothesize and dissect the neurobiological mechanisms of VNS in the treatment of primary headaches.",
keywords = "Cluster headache, Migraine, Trigeminal autonomic, Trigeminovascular, Vagus nerve stimulation",
author = "Simon Akerman and Bruce Simon and Marcela Romero-Reyes",
year = "2017",
month = "6",
doi = "10.1016/j.nbd.2017.03.004",
volume = "102",
pages = "96--104",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Vagus nerve stimulation suppresses acute noxious activation of trigeminocervical neurons in animal models of primary headache

AU - Akerman,Simon

AU - Simon,Bruce

AU - Romero-Reyes,Marcela

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Vagus nerve stimulation (VNS) has been reported to be effective in the abortive treatment of both migraine and cluster headache. Using validated animal models of acute dural-intracranial (migraine-like) and trigeminal-autonomic (cluster-like) head pain we tested whether VNS suppresses ongoing and nociceptive-evoked firing of trigeminocervical neurons to explain its abortive effects in migraine and cluster headache. Unilateral VNS was applied invasively via hook electrodes placed on the vagus nerve. A single dose of ipsilateral or contralateral VNS, to trigeminal recording and dural-stimulating side, suppressed ongoing spontaneous and noxious dural-evoked trigeminocervical neuronal firing. This effect was dose-dependent, with two doses of ipsilateral VNS prolonging suppression of ongoing spontaneous firing (maximally by ~ 60%) for up to three hours, and dural-evoked (Aδ-fiber; by ~ 22%, C-fiber: by ~ 55%) responses for at least two hours. Statistically, there was no difference between ipsilateral and contralateral groups. Two doses of VNS also suppressed superior salivatory nucleus-evoked trigeminocervical neuronal responses (maximally by ~ 22%) for 2.5 h, to model nociceptive activation of the trigeminal-autonomic pathway. VNS had no effect on normal somatosensory cutaneous facial responses throughout. These studies provide a mechanistic rationale for the observed benefits of VNS in the abortive treatment of migraine and cluster headache. In addition, they further validate these preclinical models as suitable approaches to optimize therapeutic efficacy, and provide an opportunity to hypothesize and dissect the neurobiological mechanisms of VNS in the treatment of primary headaches.

AB - Vagus nerve stimulation (VNS) has been reported to be effective in the abortive treatment of both migraine and cluster headache. Using validated animal models of acute dural-intracranial (migraine-like) and trigeminal-autonomic (cluster-like) head pain we tested whether VNS suppresses ongoing and nociceptive-evoked firing of trigeminocervical neurons to explain its abortive effects in migraine and cluster headache. Unilateral VNS was applied invasively via hook electrodes placed on the vagus nerve. A single dose of ipsilateral or contralateral VNS, to trigeminal recording and dural-stimulating side, suppressed ongoing spontaneous and noxious dural-evoked trigeminocervical neuronal firing. This effect was dose-dependent, with two doses of ipsilateral VNS prolonging suppression of ongoing spontaneous firing (maximally by ~ 60%) for up to three hours, and dural-evoked (Aδ-fiber; by ~ 22%, C-fiber: by ~ 55%) responses for at least two hours. Statistically, there was no difference between ipsilateral and contralateral groups. Two doses of VNS also suppressed superior salivatory nucleus-evoked trigeminocervical neuronal responses (maximally by ~ 22%) for 2.5 h, to model nociceptive activation of the trigeminal-autonomic pathway. VNS had no effect on normal somatosensory cutaneous facial responses throughout. These studies provide a mechanistic rationale for the observed benefits of VNS in the abortive treatment of migraine and cluster headache. In addition, they further validate these preclinical models as suitable approaches to optimize therapeutic efficacy, and provide an opportunity to hypothesize and dissect the neurobiological mechanisms of VNS in the treatment of primary headaches.

KW - Cluster headache

KW - Migraine

KW - Trigeminal autonomic

KW - Trigeminovascular

KW - Vagus nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=85015433489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015433489&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2017.03.004

DO - 10.1016/j.nbd.2017.03.004

M3 - Article

VL - 102

SP - 96

EP - 104

JO - Neurobiology of Disease

T2 - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -